# The Protein Brewery

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/the-protein-brewery-b-v

- Industry: Food
- Headquarters: Breda, Netherlands
- Website: www.theproteinbrewery.com/
- Total disclosed funding: $81M
- Latest round: Series B (Jun 29, 2026)
- Investors on record: 7

## About

Founded in 2020 by Wim de Laat and based in Breda, Netherlands, The Protein Brewery develops fungi-based protein by using only a fraction of available land and water using a biotic production process to replace animal-based protein products. In June 2026, The Protein Brewery completed an EUR 18 million extension of its Series B funding round led by ABN AMRO Sustainable Impact Fund, with participation from Invest-NL, Novo Holdings, Madeli, and Brabant Development Agency (BOM). Combined with the company's  EUR 30 million Series B round completed in September 2025, the Series B financing totals EUR 48 million. The company will use the funding to reach commercial scale for its fungi-based protein ingredient and prepare for a U.S. launch. The Protein Brewery generates revenue by licensing its proprietary fermentation technology and selling Fermotein mycoprotein ingredients to food manufacturers, enabling sustainable protein solutions for plant-based products, snacks, and alternative dairy applications.

## Funding rounds

- Series B, Jun 29, 2026, $20M — Novo Holdings, BOM Brabant Ventures, ABN AMRO, Invest-NL, Madeli
- Series B, Sep 4, 2025, $35M — Novo Holdings, BOM Brabant Ventures, Unovis Asset Management, Invest-NL, Madeli
- Series A, Oct 1, 2020, $26M — Novo Holdings, Roquette Ventures, Unovis Asset Management

## Investors

- Novo Holdings — Series A, Series B
- Roquette Ventures (https://capitalatlas.ai/funds/roquette-ventures) — Series A
- Unovis Asset Management (https://capitalatlas.ai/funds/unovis-asset-management) — Series A, Series B
- BOM Brabant Ventures (https://capitalatlas.ai/funds/bom-brabant-ventures) — Series B
- Invest-NL — Series B
- Madeli — Series B
- ABN AMRO (https://capitalatlas.ai/funds/abn-amro) — Series B